개 아토피 피부염 시장 기회, 성장 촉진 요인, 산업 동향 분석, 예측(2025-2034년)

The Global Canine Atopic Dermatitis Market was valued at USD 1.4 billion in 2024 and is projected to expand at a robust CAGR of 8.9% from 2025 to 2034. This surge in market growth is driven by an increasing number of dogs diagnosed with atopic dermatitis and a growing focus on the health and well-being of companion animals. Pet owners are becoming more vigilant about their pets' wellness, leading to a spike in demand for advanced veterinary dermatology treatments. As pet care continues to evolve, the market is witnessing a shift towards more effective and specialized treatments, which is further driving the expansion. Additionally, the global trend of humanizing pets and treating them like family members is fueling market growth. These factors collectively contribute to a significant boost in demand for medications, diagnostics, and treatments that can offer lasting relief from the condition.

The ongoing advancements in veterinary medicine are also playing a crucial role in market progression. The availability of innovative treatments such as monoclonal antibodies and newer, safer therapies is gaining widespread acceptance. These treatments are particularly appreciated for their effectiveness in alleviating itching and inflammation, which are the primary symptoms of canine atopic dermatitis. As these therapies continue to improve, their demand is expected to increase, and this will further accelerate market growth. Notably, there has been a rise in research and development activities that continue to introduce groundbreaking solutions, positioning the market for continued success.

The market is segmented by product type, including glucocorticoids, antihistamines, immunosuppressants, monoclonal antibodies, and other therapies. Glucocorticoids dominated the market, valued at USD 477.1 million in 2024. Medications such as prednisone and dexamethasone are commonly used in treating severe or acute cases of atopic dermatitis, providing rapid relief from inflammation. Despite the arrival of newer, costlier treatments like monoclonal antibodies and oral JAK inhibitors, glucocorticoids remain a popular option due to their effectiveness, affordability, and widespread availability. This accessibility makes them especially useful in regions where advanced veterinary care might not be readily available.

The market is further divided by route of administration, encompassing oral, topical, and injectable treatments. The oral segment led the market in 2024, holding a 47.2% share. Oral treatments are often preferred by pet owners due to their ease of use, which enhances adherence to prescribed treatment regimens. These therapies offer quick relief from symptoms such as itching and inflammation, often showing results within a few hours to days.

The U.S. canine atopic dermatitis market, valued at USD 528 million in 2024, is expected to reach USD 1.2 billion by 2034. The U.S. continues to hold a prominent position in the global market, driven by a rise in awareness regarding pet healthcare and a significant increase in the number of dogs suffering from atopic dermatitis. The adoption of advanced diagnostic tools and therapies, coupled with the presence of key industry players offering innovative solutions, is expected to sustain the growth of the U.S. market. As pet owners become more knowledgeable and concerned about their pets' conditions, the demand for effective treatment options is set to rise substantially.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising pet ownership and humanization of pets
    • 3.2.1.2 Increased awareness of skin disorders and advanced treatment options
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects of few medications
    • 3.2.2.2 Off-label use of human drugs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Glucocorticoids
• 5.3 Antihistamines
• 5.4 Immunosuppressants
• 5.5 mAbs
• 5.6 Other products

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Topical
• 6.4 Injectable

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Retail pharmacies
• 7.3 Veterinary hospital pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AB Science
• 9.2 Boehringer Ingelheim
• 9.3 Ceva
• 9.4 Dechra Veterinary Products
• 9.5 Elanco
• 9.6 Kindred Biosciences
• 9.7 Nextmune (Vimian)
• 9.8 Phibro Animal Health Corporation
• 9.9 Toray Industries
• 9.10 Vetoquinol
• 9.11 Virbac
• 9.12 Zoetis